Optimer Pharmaceuticals
San Diego · Founded 1998
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
Company Facts
- Founded: 1998
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Total funding: $66.2M
- Funding stage: M&A
- Last round: Series D (Dec 2005)
- Ticker: nasdaq:OPTR
- Website: optimerpharma.com
- Phone: +8589090737
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/optimer-pharmaceuticals-2210150 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.